• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke
DISCUSSION: Pioglitazone use is associated with a lower risk of dementia in DM patients, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in DM patients.PMID:36792375 | DOI:10.1212/WNL.0000000000207069
Source: Cancer Control - February 15, 2023 Category: Cancer & Oncology Authors: Junghee Ha Dong Woo Choi None Kim Keun You Kim Chung Mo Nam Eosu Kim Source Type: research

Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
CONCLUSION: In this real-world data, the risk of stroke was comparable in T2DM patients treated with SGLT-2i or TZD.PMID:35130688 | DOI:10.4093/dmj.2021.0160
Source: Diabetes and Metabolism Journal - February 8, 2022 Category: Endocrinology Authors: Seung Eun Lee Hyewon Nam Han Seok Choi Hoseob Kim Dae-Sung Kyoung Kyoung-Ah Kim Source Type: research

PPAR agonists for the treatment of cardiovascular disease in patients with Diabetes
Conclusions: According to this study, Pioglitazone treatment in type 2 diabetes patients and hypersensitive Ischemic stroke patients is linked to minor ischemic stroke which is recurrent in Asian people. Pioglitazone and the telmisartan treatment have an increasing pleiotropic effect related to the higher PPAR- gamma effects. Further research needs to be conducted with the PPAR mechanism ' s details to confirm the PPAR effect on Ischemic stroke treatment. [Ethiop. J. Health Dev. 2021; 35(3): 249-257]Keywords: PPAR agonist, Dyslipidaemia, Thiazolidinediones, Type 2 diabetes, Pioglitazone, PPAR-alpha, PPAR-gamma, Insulin resistance, Alecardio.
Source: Ethiopian Journal of Health Development - November 25, 2021 Category: African Health Authors: Zheng Xia, Guo Lixia, Zhang Zhijun Source Type: research

Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research